Significantly more patients with obesity took metformin, β-blocker, α2 adrenergic receptor agonist methyldopa, acetylsalicylic acid, and levothyroxine but there was no significant difference between the two groups with respect to the usage of angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, Ca2+-channel blockers, imidazolidine or α2 adrenergic receptor agonists, statins, and diuretics. Here, ACE is linked to obesity due to melanocortin 4 receptor deficiency.